American Association for Cancer Research
10780432ccr200418-sup-236654_2_supp_6200233_q9hzb0.pptx (19.42 MB)

Supplementary from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Download (19.42 MB)
posted on 2023-03-31, 21:50 authored by Wungki Park, Jiapeng Chen, Joanne F. Chou, Anna M. Varghese, Kenneth H. Yu, Winston Wong, Marinela Capanu, Vinod Balachandran, Caitlin A. McIntyre, Imane El Dika, Danny N. Khalil, James J. Harding, Nima Ghalehsari, Zoe McKinnell, Sree B. Chalasani, Vladimir Makarov, Pier Selenica, Xin Pei, Nicolas Lecomte, David P. Kelsen, Ghassan K. Abou-Alfa, Mark E. Robson, Liying Zhang, Michael F. Berger, Nikolaus Schultz, Timothy A. Chan, Simon N. Powell, Jorge S. Reis-Filho, Christine A. Iacobuzio-Donahue, Nadeem Riaz, Eileen M. O'Reilly

Supplementary Data 1-8


MSK Cancer Center




Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mutations (HRm) were evaluated: BRCA1, BRCA2, PALB2, ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, and RTEL1 HRm status was grouped as: (i) germline versus somatic; (ii) core (BRCAs and PALB2) versus non-core (other HRm); and (iii) monoallelic versus biallelic. Genomic instability was compared using large-scale state transition, signature 3, and tumor mutation burden. Among 262 patients, 50 (19%) had HRD (15% germline and 4% somatic). Both groups were analyzed together due to lack of difference in their genomic instability and outcome. Median [95% confidence interval (CI)] follow-up was 21.9 (1.4–57.0) months. Median OS and PFS were 15.5 (14.6–19) and 7 (6.1–8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI: 0.29–0.67); P < 0.01], but not with 1L-non-platinum. Multivariate analysis showed HRD patients had improved OS regardless of their first-line treatment, but most had platinum exposure during their course. Biallelic HRm (11%) and core HRm (12%) had higher genomic instability, which translated to improved PFS on first-line platinum (1L-platinum) versus 1L-non-platinum. Pathogenic HRm identifies HRD in patients with PDAC with the best outcome when treated with 1L-platinum. Biallelic HRm and core HRm further enriched benefit from 1L-platinum from HRD.